What is it about?
Keloid disease is a condition where the skin produces too much scar tissue, leading to raised, thick scars that often come back after treatment. Current treatments are not always effective, so better options are needed. In this study, we tested a drug called AMA0825, which works by blocking signals in cells that control growth and movement. We examined its effects on keloid cells using different laboratory models that mimic real skin conditions. We found that AMA0825 was very effective at slowing down the growth of keloid cells, even more than commonly used steroid treatments. It also stopped these cells from multiplying by putting them into a “resting” state. In more advanced 3D models that better mimic real tissue, the drug continued to show strong effects. At higher doses, it also helped reduce features related to scar formation. When combined with a standard treatment (dexamethasone), its effects became even stronger. Overall, the study suggests that AMA0825 could be a promising new approach for treating keloid scars, especially because it works better than current treatments in controlling abnormal cell growth.
Featured Image
Why is it important?
It is important because keloid disease currently has no reliably effective treatment, and this study addresses that gap in a meaningful way. Keloids are not just cosmetic scars, they are biologically active overgrowths of skin tissue that can cause pain, itching, tightness, and major psychological distress. A key clinical problem is that they frequently recur after surgery or steroid treatment, and existing therapies often only partially suppress the disease. This study is important for three main reasons: It targets the root problem (excess cell growth) Instead of only reducing inflammation or symptoms, AMA0825 directly slows down the overactive skin cells that drive keloid formation. It shows stronger effects than current standard treatments in lab models The compound performed better than commonly used steroids in controlling abnormal cell growth, which suggests potential for improved future therapies. It uses more realistic disease models (3D spheroids) These models better mimic real keloid tissue, making the findings more relevant to how the disease behaves in the human body. In short, the study is important because it explores a new therapeutic strategy that could lead to more effective and lasting control of keloid formation, an area where current options are still limited.
Perspectives
From a perspective standpoint, this study is important because it shifts how we think about treating keloid disease, from simply suppressing inflammation to directly controlling the abnormal growth behavior of scar-forming cells. It suggests that targeting signaling pathways like ROCK could offer a more precise and mechanism-based approach, potentially leading to treatments that are more effective and less dependent on repeated steroid use. It also highlights the value of advanced 3D disease models, which better reflect real keloid tissue and can improve how future therapies are tested before moving to clinical studies. In short, the study provides a new direction for keloid research, focusing on targeted control of cell proliferation rather than temporary symptom management.
Dr Zeinab Ghasemishahrestani
University of Cape Town
Read the Original
This page is a summary of: Superior Antiproliferative and Enhanced Synergistic Effects of a ROCK Inhibitor in Multiple Models for Keloid Disease, JID Innovations, November 2025, Elsevier,
DOI: 10.1016/j.xjidi.2025.100402.
You can read the full text:
Contributors
The following have contributed to this page
